📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-27 21:24
10 analysed today
10
Today
133,648
All-time analysed
40,136
Positive
6,284
Negative
79,406
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
Beta Drugs Reports Q1-FY27 Revenue of ₹125.5 Cr and 21.8% EBITDA Margin
Beta Drugs Limited (BETA) demonstrated strong operational momentum in Q1-FY27, reporting revenue of ₹125.5 Cr, which represents approximately 26% of its TTM revenue in a single quarter. EBITDA margins improved to 21.83% in Q1-FY27 from 19.67% in FY26, driven by a high-margin oncology portfolio and new product launches. The company has strategically diversified into the IVF segment through the 66.09% acquisition of Nivian Life Sciences in April 2026. With a massive pipeline of 623 dossier registrations globally, the company is positioning itself for significant export-led growth.
Confidence: HIGH
What changedBeta Drugs has transitioned into a multi-specialty player by adding IVF to its core Oncology and Dermatology portfolio, while reporting a strong margin expansion in Q1-FY27.
Why it mattersThe diversification into IVF and the aggressive global dossier filing strategy reduce therapeutic concentration risk and provide a clear roadmap for sustaining 20-25% growth rates.
Q1-FY27 Revenue: ₹125.5 CrQ1 Revenue vs TTM Revenue: ~26%Q1-FY27 EBITDA Margin: 21.83%Dossier Pipeline: 623Nivian Acquisition Stake: 66.09%FY26 ROCE: 31.03%
📅 Short termThe strong Q1-FY27 performance and margin expansion are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift toward regulated markets and backward integration into APIs supports long-term margin stability and scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High working capital cycle (107 days in FY26)
- Regulatory risks in diverse export markets (LATAM/MENA)
- Intense competition in the CDMO segment (39% of revenue)
Key Highlights
Q1-FY27 revenue reached ₹125.5 Cr with an improved EBITDA margin of 21.83%
Acquired 66.09% stake in Nivian Life Sciences in April 2026 to enter the IVF therapy segment
Dossier registration pipeline stands at 623 units across LATAM, APAC, MENA, and CIS markets
New products contributed 25% to the total revenue in FY26, highlighting R&D efficiency
Debt-to-Equity ratio improved to 0.60x in FY26 from 0.70x in FY25
👀 What to Watch
Investors should monitor the revenue contribution from the newly acquired IVF business (Nivian) and the conversion rate of the 623-dossier pipeline into active export sales in regulated markets.
40.9% PAT Growth in Q1FY27; Beta Drugs Reports Rs 125.55 Cr Sales and Margin Expansion
Beta Drugs Limited reported a strong Q1FY27 with consolidated sales growing 25.3% YoY to Rs 125.55 Cr. Net profit surged 40.92% to Rs 16.5 Cr, significantly aided by a 64% reduction in interest costs following the conversion of CCDs in May 2026. Operating performance was robust with gross margins expanding to 56.6% (vs 50.4% YoY) driven by a shift toward high-margin branded oncology products, which grew 47% YoY. The company maintained its FY27 revenue growth guidance of 20-25%.
Confidence: HIGH
What changedBeta Drugs reported its Q1FY27 financial results, showing significant margin improvement and a reduction in financial leverage through debt-to-equity conversion.
Why it mattersThe results validate the company's strategy of shifting toward branded oncology and exports, which carry higher margins than the CMO segment. The reduction in interest costs structurally improves the bottom line.
Consolidated Sales (Q1): Rs 125.55 CrQ1 Revenue vs TTM Revenue: 26.1%Net Profit Growth (YoY): 40.92%Gross Margin: 56.6%Interest Cost Reduction: 64.3%FY27 Growth Guidance: 20-25%
📅 Short termThe stock is likely to react positively to the margin expansion and strong double-digit growth across all business segments.
📈 Long termThe structural shift toward a branded-heavy mix (aiming for >80% by 2030) and backward integration into APIs suggests sustainable margin improvement over the coming years.
⚠ Risk flags
- Regulatory delays in export markets (Mexico/Vietnam)
- Intense competition in the CMO segment leading to price erosion
Key Highlights
Consolidated total sales reached Rs 125.55 Cr, a 25.3% increase from Rs 100.2 Cr in Q1FY26.
Net Profit grew 40.92% YoY to Rs 16.5 Cr, representing ~32% of the total TTM PAT.
Branded Oncology segment delivered 47% YoY growth, recording sales of Rs 33.0 Cr.
Interest costs decreased to Rs 0.75 Cr from Rs 2.1 Cr YoY due to CCD conversion.
Consolidated EBITDA (excluding other income) grew by 38.9% YoY to Rs 27.37 Cr.
👀 What to Watch
Watch for the execution of the 'Vision 2030' strategy, specifically the ramp-up in export markets like Mexico and South Africa and the launch of new NDDS products in FY27.
Beta Drugs Completes Acquisition of 66.09% Stake in Nivian Lifesciences
Beta Drugs Limited has finalized the acquisition of 10,94,535 equity shares of Nivian Lifesciences Private Limited, representing a 66.09% controlling stake. The acquisition was completed through a share swap arrangement, with the final tranche of shares transferred on May 22, 2026. Consequently, Nivian Lifesciences has become a subsidiary of Beta Drugs. The company is now initiating the process for NSE listing approval for the shares issued under the swap agreement.
Key Highlights
Acquired 10,94,535 equity shares representing 66.09% of Nivian Lifesciences Private Limited
Nivian Lifesciences became a subsidiary of Beta Drugs Limited in April 2026
The acquisition was structured as a share swap arrangement
Final share transfer completed on May 22, 2026, following an initial 64.26% transfer in April
Company to seek NSE listing approval for shares issued under the corporate action
👀 What to Watch
Investors should track the integration of Nivian Lifesciences and its contribution to the consolidated bottom line. While the share swap will result in equity dilution, the focus should be on the long-term synergies and market expansion provided by the new subsidiary.
Beta Drugs Allots 6.65 Lakh Equity Shares via CCD Conversion to Institutional Investors
Beta Drugs Limited has approved the allotment of 6,65,314 equity shares of ₹10 each following the conversion of Compulsory Convertible Debentures (CCDs). These CCDs were originally issued in November 2024 to Healthquad Trust II and Inti Capital VCC. The conversion was executed at a 1:1 ratio, which will lead to an increase in the company's paid-up equity share capital. This action represents the conclusion of a prior institutional fundraising round.
Key Highlights
Allotment of 6,65,314 equity shares with a face value of ₹10 each.
Conversion of CCDs issued on November 27, 2024, at a 1:1 ratio.
Shares allotted to institutional investors Healthquad Trust II and Inti Capital VCC - Inti Capital I.
The board meeting concluded at 11:45 a.m. on May 25, 2026.
👀 What to Watch
Investors should account for the slight dilution in Earnings Per Share (EPS) due to the increased share count. The conversion by institutional investors is a positive sign of long-term commitment to the company.
Beta Drugs FY26 Revenue Hits ₹396 Cr; Targets ₹900 Cr+ Revenue by 2030 via Vision 2030
Beta Drugs reported a revenue growth of 7.6% to ₹396 crores in FY26, with EBITDA margins expanding to 22.57%. The company successfully acquired a 66.1% stake in Nivian Lifesciences for ₹69.4 crores to enter the high-growth IVF segment, which will be consolidated in FY27. Despite an 11% dip in exports due to tender delays, management expects a 50% rebound in this segment for FY27. The company has outlined 'Vision 2030' aiming to more than double revenues to over ₹900 crores within the next four years.
Key Highlights
Revenue increased to ₹396 crores while EBITDA grew 12.8% to ₹86.85 crores with margins at 22.57%.
Acquired 66.1% stake in Nivian Lifesciences for ₹69.4 crores to enter the IVF market (FY26 revenue ~₹45 Cr).
Branded oncology sales grew 20% to ₹123 crores; Derma business grew 35% to ₹16.58 crores.
Management targets ₹900+ crores revenue by FY30 with EBITDA margins expected to reach 23-24%.
Export segment poised for 50% growth in FY27 following the award of delayed tenders in March 2026.
👀 What to Watch
Investors should monitor the integration of the Nivian acquisition and the recovery of the export business in Q1 FY27. The stock remains attractive for long-term investors given the 'Vision 2030' growth targets and improving margin profile.
Beta Drugs FY26 Revenue Hits ~385 Cr; EBITDA Margins Expand to 22.57%
Beta Drugs Limited delivered a robust FY26 performance with total revenue reaching approximately 385 Cr, led by the CDMO (149 Cr) and Branded Oncology (140 Cr) segments. Profitability improved significantly as EBITDA margins rose to 22.57% from 21.10% YoY, supported by a gross margin expansion to 55.52%. The company's IVF foray, Nivian, showed strong momentum reaching 43 Cr in sales, while the Dermatology segment achieved monthly breakeven. Financial health remains stable with the debt-to-equity ratio improving to 0.63 and a cash reserve of 124.84 Cr.
Key Highlights
EBITDA margins expanded to 22.57% in FY26, up from 21.10% in FY25, driven by high-margin product focus.
Branded Oncology segment reached 140 Cr revenue with 7 brands now generating over 5 Cr each.
Nivian (IVF segment) sales grew to 43 Cr in FY26, nearly tripling from 15 Cr in FY23.
API sales increased by 24% to 24.8 Cr, with 80% of formulation APIs now manufactured in-house for cost efficiency.
Debt-to-Equity ratio improved to 0.63 from 0.74 YoY, while maintaining a strong cash position of 124.84 Cr.
👀 What to Watch
Investors should note the successful margin expansion and diversification into high-growth IVF and Dermatology markets. The company's 'Vision 2030' roadmap suggests a strategic shift toward a 50% CDMO revenue mix, which could provide long-term stability and repeat business.
Beta Drugs Allots 2.83 Lakh Shares at ₹1712.49 for Nivian Lifesciences Acquisition
Beta Drugs Limited has approved the allotment of 2,83,668 equity shares as part of its acquisition of Nivian Lifesciences Private Limited. The shares are being issued at a price of ₹1712.49 each, which includes a substantial premium of ₹1702.49 per share. This equity-based acquisition strategy allows the company to expand its portfolio while utilizing its stock as currency. The board finalized this decision in its meeting held on April 25, 2026.
Key Highlights
Allotment of 2,83,668 equity shares to acquire Nivian Lifesciences Private Limited.
Issue price of ₹1712.49 per share, featuring a premium of ₹1702.49.
Face value of the newly issued shares is ₹10 per share.
The board meeting concluded on April 25, 2026, after nearly three hours of deliberation.
👀 What to Watch
Investors should evaluate the strategic fit of Nivian Lifesciences and monitor the impact on future EPS due to equity dilution. The high premium pricing reflects management's confidence in the company's current market valuation.
Beta Drugs Expands Global Footprint with Regulatory Milestones in Azerbaijan and Philippines
Beta Drugs Limited has achieved significant regulatory progress, completing a successful GMP inspection by Azerbaijan's Ministry of Health with final approval expected within 1-2 months. In the Philippines, the company secured Certificates of Product Registration for 2 brands, representing the first generic versions of these products in that market. These developments are part of a broader strategy to penetrate the CIS and Southeast Asian markets, including Vietnam and Thailand. Furthermore, the company has triggered an EU GMP inspection, signaling an intent to enter highly regulated European markets.
Key Highlights
Successful Azerbaijan Ministry of Health inspection conducted from April 13-17, 2026, with GMP approval expected in 1-2 months.
Secured Certificates of Product Registration (CPR) for 2 brands in the Philippines as the first generic approvals in that market.
Anticipates additional product approvals in the Philippines within the next 6 months to facilitate entry into Vietnam and Thailand.
Triggered EU GMP inspection to build upon existing approvals from PIC/S, ANVISA, INVIMA, and EAEU.
👀 What to Watch
Investors should monitor the conversion of these regulatory approvals into export revenue growth over the next 2-4 quarters. The successful trigger of an EU GMP inspection is a significant qualitative milestone that could re-rate the stock if successful.
Beta Drugs Clarifies Shareholding Post-Preferential Issue; Promoter Stake to Dilute to 59.10%
Beta Drugs Limited has provided a clarification to the National Stock Exchange regarding its shareholding pattern following a proposed preferential issue of equity shares and Compulsorily Convertible Debentures (CCDs). The total share count is projected to increase from 1,01,36,890 to 1,10,85,872 shares on a fully diluted basis. This issuance will result in the promoter holding diluting from 64.63% to 59.10%, while institutional investor participation is expected to rise significantly from 3.43% to 9.14%. The clarification follows observations raised by the NSE concerning the company's EGM notice.
Key Highlights
Total equity shares to increase from 1,01,36,890 to 1,10,85,872 on a fully diluted basis
Promoter shareholding to decrease from 64.63% to 59.10% post-issue
Institutional investor holding to increase from 3.43% (3,48,268 shares) to 9.14% (10,13,582 shares)
Indian public shareholding to rise slightly from 21.68% to 22.35%
Clarification issued in response to NSE letter dated March 30, 2026, regarding EGM corrigendum
👀 What to Watch
Investors should note the 9.36% equity dilution and monitor how the raised capital is deployed to drive future earnings. The significant increase in institutional holding is a positive indicator of professional investor confidence in the company's growth trajectory.
Beta Drugs Clarifies Post-Preferential Offer Shareholding for 33 Allottees
Beta Drugs Limited has provided a detailed clarification to the National Stock Exchange regarding its proposed preferential offer. The disclosure lists 33 allottees and their respective post-issue shareholding percentages to ensure regulatory compliance. The largest individual allocation in this list is to Anjali Ajit Deval, who will hold 1.1329% of the company's post-offer capital. This clarification follows a corrigendum to the Notice of the Extra Ordinary General Meeting originally dated January 9, 2026.
Key Highlights
Disclosure of post-preferential offer capital for 33 specific allottees.
Anjali Ajit Deval emerges as the largest allottee in this list with 1,25,596 shares (1.1329%).
Kayadam Ramanathan Bharat and Neha Bagla to hold 0.4256% and 0.3087% respectively post-allotment.
The list includes several institutional and individual investors with holdings ranging from 0.0018% to 1.1329%.
👀 What to Watch
Investors should note the progress of the preferential fundraise and the resulting equity dilution. Monitor the final allotment and the company's stated purpose for the raised capital.
Beta Drugs Clarifies Nivian Lifesciences Acquisition and 10% Equity Dilution
Beta Drugs Limited has provided detailed clarifications regarding its acquisition of Nivian Lifesciences and the associated preferential issue. The transaction involves a share swap ratio of 37 Beta shares for every 100 Nivian shares, alongside a cash consideration totaling approximately ₹20.82 crore. Post-issue, the promoter holding will dilute from 64.90% to 59.10%, while institutional investor participation is set to rise significantly from 3.03% to 9.14%. The total share capital will expand to 1.11 crore shares to facilitate this inorganic growth.
Key Highlights
Promoter shareholding to dilute from 64.90% to 59.10% post-preferential issue.
Institutional investor stake to increase substantially from 3.03% to 9.14%.
Acquisition involves a share swap of 2,83,668 Beta shares at a 37:100 ratio.
Total cash consideration for the acquisition components is approximately ₹20.82 crore.
Total equity base to expand from 1,00,94,553 to 1,10,85,872 shares.
👀 What to Watch
Investors should view the increased institutional interest as a positive sign, but should monitor how the Nivian Lifesciences acquisition contributes to earnings to offset the ~10% equity dilution.
Beta Drugs Q3 Results: PAT at ₹8.51 Cr; FY26 Revenue Guidance Cut to ₹400 Cr
Beta Drugs reported flat year-on-year revenue of ₹89.58 Crores for Q3 FY26, as a 33% surge in high-margin own branded sales was offset by a strategic exit from the low-margin CDMO Platin business. While gross margins improved significantly to 59% from 52%, EBITDA margins remained stable at 22% due to increased hiring in regulatory and manufacturing teams. The company has revised its FY26 revenue guidance downward to ₹400 Crores from ₹420 Crores but set an ambitious FY27 target of ₹530 Crores. Net profit was impacted by rising interest costs, which climbed to ₹4.43 Crores due to CCD interest obligations.
Key Highlights
Total Revenue stood flat at ₹89.58 Crores, while own branded sales grew strongly by 33% YoY.
Gross Margins saw a sharp increase to 59% in Q3FY26 compared to 52% in the previous year.
FY26 revenue outlook revised downward to ₹400 Crores due to the strategic de-focus on the Platin segment.
Interest expenses rose to ₹4.43 Crores from ₹1.87 Crores YoY, primarily on account of interest on CCDs.
Management projects FY27 revenue of ₹530 Crores with 24% EBITDA margins, driven by NDDS product launches.
👀 What to Watch
Investors should focus on the company's successful transition toward higher-margin own brands and NDDS products despite the short-term revenue stagnation. Monitor the execution of the FY27 growth targets and the impact of geopolitical tensions on export recovery.
Beta Drugs Revises Valuation Report for Nivian Life Sciences Acquisition Using Consolidated Data
Beta Drugs Limited has announced a revision to the valuation report prepared for its proposed acquisition of Nivian Life Sciences Private Limited via a preferential issue. The registered valuer, Mr. Hitesh Jhamb, updated the report to use consolidated financial statements instead of the standalone figures used previously. This adjustment was made to provide a more comprehensive financial position under the Income and Cost approaches. The revised report, dated January 8, 2026, is now available for public inspection on the company's website.
Key Highlights
Revision of valuation report for the acquisition of Nivian Life Sciences Private Limited
Shift from standalone to consolidated financial statements for valuation methodology
Valuation updated for both Income Approach and Cost Approach metrics
Revised report dated January 8, 2026, replaces the previous version for the preferential issue
Disclosure made under Regulation 30 of SEBI LODR Regulations
👀 What to Watch
Investors should review the revised valuation report on the company website to see if the shift to consolidated financials impacts the final issue price or dilution. Monitor for further updates on the approval of the preferential issue.
Beta Drugs Shareholders Approve Preferential Issue of 2.84 Lakh Shares at ₹1,712.49
Beta Drugs Limited held an Extraordinary General Meeting on February 4, 2026, where shareholders unanimously approved all proposed resolutions. A key outcome is the approval of a preferential issue of 2,83,668 equity shares at a price of ₹1,712.49 per share, which includes a significant premium of ₹1,702.49. Additionally, the company received approval for its Employee Stock Option Plan (ESOP) 2026 and an increase in authorized share capital. These moves indicate a focus on capital infusion and talent retention through equity-based incentives.
Key Highlights
Unanimous approval (100% in favor) for the issuance of 2,83,668 equity shares on a preferential basis.
Preferential issue price set at ₹1,712.49 per share, featuring a premium of ₹1,702.49 over the ₹10 face value.
Approval of the 'Beta Drugs Limited Employee Stock Option Plan 2026' for both company and group employees.
Authorized share capital increased and Memorandum of Association altered to facilitate the new share issuance.
Total of 5,969,737 valid votes were cast across all resolutions with zero votes against.
👀 What to Watch
Investors should view the successful fundraising at a high premium as a positive sign of valuation confidence. Monitor the specific use of proceeds from the preferential issue and the long-term impact of the ESOP on employee retention and equity dilution.
Beta Drugs Approves ₹48.58 Cr Fundraise via Preferential Issue and New ESOP 2026 Plan
Beta Drugs Limited held an Extraordinary General Meeting on February 04, 2026, where shareholders approved a significant fundraise through a preferential issue. The company will issue 2,83,668 equity shares at a price of ₹1712.49 per share, including a premium of ₹1702.49, totaling approximately ₹48.58 crore. Additionally, the 'Beta Drugs Limited Employee Stock Option Plan 2026' was approved to incentivize employees across the group and subsidiaries. These moves are supported by an increase in the company's Authorized Share Capital to facilitate the new issuances.
Key Highlights
Approved preferential issue of 2,83,668 equity shares at a price of ₹1712.49 per share
Total capital infusion through the preferential offer amounts to approximately ₹48.58 crore
Launch of 'Employee Stock Option Plan 2026' for employees of the company and its group entities
Increase in Authorized Share Capital and alteration of the Memorandum of Association approved
Preferential issue price includes a significant premium of ₹1702.49 over the ₹10 face value
👀 What to Watch
Investors should view the fundraise at a high premium as a sign of strong valuation support and confidence from specific investors. Monitor the company's upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Beta Drugs to Acquire Nivian Lifesciences Stake via INR 48.57 Cr Share Swap; Proposes ESOP 2026
Beta Drugs Limited has scheduled an EGM for February 4, 2026, to approve a strategic acquisition of Nivian Lifesciences Private Limited via a share swap arrangement. The company will issue 2,83,668 equity shares at a price of INR 1,712.49 per share to the sellers of the target company, representing a total value of approximately INR 48.57 crore. Additionally, the board has proposed an ESOP 2026 scheme for 2,00,000 shares (1.98% of paid-up capital) to incentivize employees. To facilitate these issuances, the authorized share capital is being raised from INR 11 crore to INR 11.40 crore.
Key Highlights
Issuance of 2,83,668 shares at INR 1,712.49 each for a non-cash consideration (share swap) to acquire Nivian Lifesciences
Proposed ESOP 2026 plan involving 2,00,000 shares, representing 1.98% of the paid-up equity as of March 2025
Authorized share capital to be increased from INR 11,00,00,000 to INR 11,40,00,000
Acquisition involves key allottees including Anjali Ajit Deval and Kayadam Ramanathan Bharat
The issue price includes a substantial premium of INR 1,702.49 per share over the face value of INR 10
👀 What to Watch
Investors should monitor the integration and growth potential of Nivian Lifesciences to justify the share dilution. The high issue price indicates strong internal valuation and confidence in the company's growth trajectory.
Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores
Beta Drugs Limited has entered into a definitive agreement to acquire a 66.09% stake in Nivian Lifesciences, a fast-growing player in the In-Vitro Fertilisation (IVF) segment. The acquisition is valued at INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian. Nivian reported net sales of INR 30.30 Crores for the 9 months ended December 2025 and is projected to reach approximately INR 43 Crores by the end of FY26. This strategic move allows Beta Drugs to diversify its portfolio into the high-growth women's health and fertility market, which is currently expanding at a 20% CAGR.
Key Highlights
Acquisition of 66.09% stake in Nivian Lifesciences for INR 69.4 Crores, valuing the company at INR 105 Crores.
Nivian reported 9M Dec'25 net sales of INR 30.30 Crores with a FY26 revenue target of ~INR 43 Crores.
Entry into the IVF therapy market, which has a total addressable size of INR 1,500-1,700 Crores in India.
Strategic synergy combining Beta's manufacturing capabilities with Nivian's marketing expertise in niche formulations.
Founder Nilesh Auti will continue to lead Nivian's operations and remain a minority shareholder.
👀 What to Watch
Investors should look favorably on this acquisition as it provides Beta Drugs entry into a high-margin, high-growth niche segment. Monitor the post-acquisition integration and the impact on consolidated earnings in the coming fiscal year.
Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores
Beta Drugs Limited has signed a definitive agreement to acquire a 66.09% majority stake in Nivian Lifesciences, valuing the target at INR 105 Crores. Nivian is a high-growth player in the In-Vitro Fertilisation (IVF) segment, which has experienced a 20% CAGR over the last five years. Nivian reported net sales of INR 30.30 Crores for the nine months ending December 2026 and expects to close FY27 at approximately INR 43 Crores. This acquisition enables Beta Drugs to diversify its portfolio into women's health and fertility, complementing its existing strengths in oncology and cosmetology.
Key Highlights
Acquisition of 66.09% stake for INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian.
Nivian projects FY27 revenue of ~INR 43 Crores, following a strong 9M performance of INR 30.30 Crores.
Entry into the IVF therapy market, which has an estimated total market size of INR 1,500-1,700 Crores.
Strategic synergy combines Beta's manufacturing cost leadership with Nivian's specialized IVF marketing and sales expertise.
Founder Nilesh Auti will continue to lead Nivian's operations, ensuring management continuity and expertise retention.
👀 What to Watch
Investors should look favorably on this acquisition as it provides Beta Drugs with a high-growth vertical outside of oncology. Monitor the post-acquisition integration and the impact on consolidated EBITDA margins in the coming fiscal year.
Beta Drugs to Acquire 66.09% Stake in Nivian Life Sciences for ₹69.40 Crores
Beta Drugs has approved the acquisition of a 66.09% majority stake in Nivian Life Sciences, a specialist in the high-growth In-Vitro Fertilisation (IVF) therapy segment. The total consideration of ₹69.40 crores will be settled through a mix of ₹20.82 crores in cash and ₹48.58 crores via a share swap, issuing 2,83,668 shares at ₹1,712.49 per share. Nivian reported a turnover of ₹29.12 crores and an EBITDA of ₹4.22 crores for FY25. The board also approved a new ESOP scheme for 2,00,000 shares and an increase in authorized share capital.
Key Highlights
Acquisition of 66.09% stake in Nivian Life Sciences for a total value of ₹69.40 Crores
Consideration includes ₹20.82 Cr cash and issuance of 2,83,668 equity shares at ₹1,712.49 each
Target entity Nivian Life Sciences achieved FY25 turnover of ₹29.12 Cr and EBITDA of ₹4.22 Cr
Implementation of 'ESOP 2026' plan covering up to 2,00,000 equity shares for employees
Authorized share capital increased from ₹11.00 Cr to ₹11.40 Cr to facilitate the share swap
👀 What to Watch
Investors should monitor the integration of Nivian's IVF portfolio, which offers high-growth synergies with Beta's existing oncology distribution network. The acquisition valuation at approximately 16.4x EBITDA appears strategic for entry into a niche pharmaceutical segment.
Beta Drugs to Consider Acquisition and Preferential Share Issue on January 9
Beta Drugs Limited has scheduled a board meeting for January 9, 2026, to deliberate on a strategic acquisition of a target company. The company intends to issue equity shares on a preferential basis to the target's shareholders as consideration for the deal, effectively an equity swap. Additionally, the board will consider the implementation of an Employee Stock Option Plan (ESOP). The trading window remains closed as these developments are deemed price-sensitive alongside the upcoming financial results.
Key Highlights
Board meeting scheduled for January 9, 2026, to approve a target company acquisition.
Proposed issuance of equity shares on a preferential basis as non-cash consideration for the acquisition.
Introduction of an Employee Stock Option Plan (ESOP) to be considered by the board.
Trading window closure extended until 48 hours after the declaration of financial results.
The acquisition and share issuance are classified as price-sensitive information under SEBI regulations.
👀 What to Watch
Investors should watch for the January 9 board outcome to understand the valuation of the target company and the extent of equity dilution. The move indicates an aggressive inorganic growth strategy which could be a long-term positive for the stock.
